Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.83 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.83 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.83 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.83 |
| ▸ | GCGR | P47871 | 6/20 | 0.83 |
| ▸ | RAF1 | P04049 | 5/20 | 0.80 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.79 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16667652 | 0.98 | MAPK13 (0.83) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL104130 | 0.98 | MAPK13 (0.82) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| Benzene SCHEMBL28852698 | 0.98 | MAPK13 (0.82) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| Methane SCHEMBL3278320 | 0.96 | MAPK13 (0.79) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL27850480 | 0.96 | MAPK13 (0.79) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL3456136 | 0.92 | MAPK13 (0.74) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL739928 | 0.91 | MAPK13 (0.72) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL23710761 | 0.91 | KDM4E (0.78) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL9619859 | 0.91 | MAPK13 (0.85) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL2127491 | 0.91 | MAPK13 (0.85) | MAPK13MAPK12MAPK11MAPK14GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452989-B2 | Compounds, sensors, methods, and systems for detecting gamma radiation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-09-27 | — | — | US | claimed |
| US-20150118758-A1 | COMPOUNDS, SENSORS, METHODS, AND SYSTEMS FOR DETECTING GAMMA RADIATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-30 | — | — | US | claimed |
| WO-2013177539-A1 | COMPOUNDS, SENSORS, METHODS, AND SYSTEMS FOR DETECTING GAMMA RADIATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-11-28 | — | — | WO | claimed |
| JP-3128357-A | — | — | None | — | — | JP | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024141952-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | NOVOCURE GMBH (CH) | 2024-07-04 | — | — | WO | disclosed |
| US-20240216403-A1 | METHODS AND COMPOSITIONS FOR INHIBITING FIBROBLAST ACTIVATION | BIOPHARMA CREDIT PLC (GB) | 2024-07-04 | — | — | US | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11285151-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-7329715-B2 | Abrasion resistant coatings by siloxane oligomers | YAZAKI CORPORATION (JP) | 2008-02-12 | — | — | US | disclosed |
| US-20070112061-A1 | Heat- or singlet oxygen-generating agents and cancer treatment compositions comprising organic peroxide or chemiluminescent compound | MANAC INC. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112061-A1 | Heat- or singlet oxygen-generating agents and cancer treatment compositions comprising organic peroxide or chemiluminescent compound | MANAC INC. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20060235178-A1 | Abrasion resistant coatings by siloxane oligomers | STOWE WOODWARD LLC | 2006-10-19 | — | — | US | disclosed |
| US-5904994-A | OXAZOLE, IMIDAZOLE, QUINOLINE AND PYRAZINE COMPOUNDS; WHITE LIGHT EMITTERS | LUCENT TECHNOLOGIES INC. (US) | 1999-05-18 | — | — | US | disclosed |
| EP-0763965-A2 | Blue-emitting materials and electroluminescent devices containing these materials | LUCENT TECHNOLOGIES INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| JP-H03128357-A | NOVEL FLUORESCENT SUBSTANCE | JAPAN CARLIT CO LTD:THE | 1991-05-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112061-A1 | Heat- or singlet oxygen-generating agents and cancer treatment compositions comprising organic peroxide or chemiluminescent compound | HSPE1, MCL1, HMOX1 | MAPK13 1707/4885MAPK12 861/4885MAPK11 714/4885 |
| US-20150118758-A1 | COMPOUNDS, SENSORS, METHODS, AND SYSTEMS FOR DETECTING GAMMA RADIATION | RAD50, MRE11, IRF3 | MAPK13 3656/4885MAPK12 2323/4885MAPK11 2628/4885 |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | MAPK13 2184/4885MAPK12 2658/4885MAPK11 2335/4885 |
| US-11285151-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | MAPK13 2184/4885MAPK12 2658/4885MAPK11 2335/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | MAPK13 2184/4885MAPK12 2658/4885MAPK11 2335/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | MAPK13 1248/4885MAPK12 1041/4885MAPK11 810/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | MAPK13 2184/4885MAPK12 2658/4885MAPK11 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.